| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.42 | 1e-15 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.4 | 5e-15 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.36 | 1e-09 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.23 | 1e-08 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.23 | 1e-08 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.21 | 6e-08 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.22 | 6e-08 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.22 | 6e-08 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.21 | 7e-08 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.21 | 8e-08 |